SCHEMBL6693886

SCHEMBL6693886

N#Cc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2)c(S(=O)(=O)N2CCNCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.47
HTR6 P50406 1/20 0.43
CNR1 P21554 1/20 0.41
MAPT P10636 1/20 0.41
TRPV4 Q9HBA0 12/20 0.40
ACLY P53396 1/20 0.40
CYP3A4 P08684 2/20 0.39
KCNH2 Q12809 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
PPARG P37231 1/20 0.39
FKBP1A P62942 1/20 0.39
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2819901 0.83 USP2 (0.48) USP2CNR1MAPTTRPV4CYP3A4
SCHEMBL2821659 0.83 USP2 (0.50) USP2CNR1MAPTTRPV4CYP3A4
Hydrochloric Acid SCHEMBL2823513 0.82 USP2 (0.47) USP2CNR1MAPTTRPV4CYP3A4
Hydrochloric Acid SCHEMBL2823037 0.82 USP2 (0.49) USP2CNR1MAPTTRPV4CYP3A4
SCHEMBL2824037 0.76 KMT2A (0.49) USP2CNR1MAPTTRPV4TRPM8
SCHEMBL2823894 0.76 USP2 (0.48) USP2CNR1MAPTTRPV4CYP3A4
Hydrochloric Acid SCHEMBL2822124 0.76 USP2 (0.47) USP2CNR1MAPTTRPV4CYP3A4
SCHEMBL2820657 0.75 USP2 (0.46) USP2CNR1MAPTTRPV4CYP3A4
SCHEMBL2818819 0.75 USP2 (0.46) USP2CNR1MAPTTRPV4CYP3A4
SCHEMBL3836390 0.74 USP2 (0.45) USP2CNR1MAPTTRPV4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461038-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS Bayer HealthCare AG (DE) 2004-09-29 EP claimed
WO-2003022277-A1 ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS BAYER HEALTHCARE AG (DE) 2003-03-20 WO claimed